Olympiad Research’s Inovio Pharmaceuticals INO Stock Holding History

Olympiad Research’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$29K	Hold	1,396	–	–	0.02%	248
2022 Q2	$29K	Buy	+1,396	New	+$39.3K	0.01%	271

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Olympiad Research's INO Position: Q3 2022 in Review

Olympiad Research held its Inovio Pharmaceuticals (INO) position steady in Q3 2022 at 1,396 shares worth $29K. The position accounts for 0.02% of the portfolio, ranked #248.

Olympiad Research first reported a position in INO in Q2 2022 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold INO as of Q3 2022.

Olympiad Research held 1,396 shares of Inovio Pharmaceuticals worth $29K as of Q3 2022.
Olympiad Research left its Inovio Pharmaceuticals share count unchanged in Q3 2022.
Inovio Pharmaceuticals made up 0.02% of Olympiad Research's portfolio in Q3 2022, its #248 holding.
Olympiad Research first reported a position in Inovio Pharmaceuticals in Q2 2022 and has held it in 2 quarters since.
182 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2022.

Based on Olympiad Research's 13F filing for Q3 2022, filed 7 Nov 2022.